Ivermectin, Fenbendazole and Mebendazole in Cancer: Patient Benefits Confirmed in a 2026 Study
Nicolas Hulscher and colleagues conducted a survey of 197 Cancer patients taking Ivermectin and Mebendazole for 6 months (abstract below) and confirmed:
This confirms what we've seen in the 9000+ Cancer patients we helped in our largest Ivermectin Cancer Project in the world! I've often talked about a 75-80% clinical benefit that patients reported when they came to us, with some cancer patients getting tumor shrinkage, some getting stabilization of disease and some succeeding in preventing recurrence!
Methods: We analyzed a prospective observational cohort of 197 cancer patients who were prescribed ivermectin and mebendazole off-label through a telemedicine platform by licensed U.S. healthcare providers. Participants received compounded oral capsules containing 25 mg ivermectin and 250 mg mebendazole. As part of a clinical program evaluation, data were collected via voluntary, standardized digital surveys at baseline and at approximately 6-month follow-up. Of the initial cohort (N = 197), baseline characteristics, including cancer type and disease status, were assessed. A total of 122 participants completed the follow-up survey (61.9% response rate) to evaluate self-reported cancer outcomes, medication adherence, and adverse events. 95% confidence intervals (CI) were calculated for primary outcome measures using the Wilson score method. Dose-stratified analyses for outcomes and safety were conducted using Chi-square statistics.
Results: The cohort represented a diverse clinical profile of cancer patients, with mean age of 67 years and nearly balanced sex distribution (52.3% male, 47.7% female). Cancer types included prostate (27.9%), breast (18.3%), lung (8.6%), colon (5.1%), urologic (4.6%), pancreatic (3.0%), liver (2.5%), gynecologic (2.5%), and hematologic (2.5%) malignancies. At enrollment, participants had a median duration since initial diagnosis of 1.2 years, with 37.1% experiencing active disease progression. At 6-month follow-up, medication adherence was high with 86.9% of participants completing the full initial 90-capsule ivermectin-mebendazole prescription and 66.4% remaining on the protocol at 6 months. The Clinical Benefit Ratio (CBR) was 84.4% (95% CI: 77.0–89.8%). Notably, 48.4% (95% CI: 39.7–57.1%) of the cohort reported the strongest positive outcomes, consisting of regression (15.6%; 95% CI: 10.2–23.0%) or no current evidence of disease (NED, 32.8%; 95% CI: 25.1–41.5%). Disease stability was reported to be maintained in 36.1% (95% CI: 28.1–44.9%) of participants, while 15.6% (95% CI: 10.2–23.0%) reported disease progression. While 25.4% reported mild side effects (primarily gastrointestinal), 93.6% of those affected continued treatment through minor dose adjustments. Some participants reported concurrent conventional therapies, including chemotherapy (27.9%), radiation therapy (21.3%), and surgery (19.7%), as well as adjunctive interventions such as supplement use (49.2%), dietary modification (37.7%), and other integrative approaches.
Conclusions: In this prospective real-world cohort, the combination of ivermectin and mebendazole was associated with high rates of self-reported clinical benefit, with nearly half of participants reporting tumor regression or no current evidence of disease across a heterogeneous population of cancer patients. These findings provide a compelling clinical signal that these well-tolerated, repurposed agents may offer therapeutic benefit. However, given the observational design, reliance on self-reported outcomes, and potential for selection bias and uncontrolled confounding, these findings should be interpreted as hypothesis-generating. Urgent prospective, randomized, placebo-controlled clinical trials are warranted to validate these observations and further define optimal dosing strategies.
Among other conventional cancer therapies – with surgery as the most common treatment reported in 83 participants (42.1%) - they also reported making diet and lifestyle changes like intermittent or prolonged fasting, ketogenic or low-sugar diets, hyperbaric oxygen, red-light therapy, and specific supplements (e.g., vitamin D, turmeric, berberine, mushrooms – all found in TWC’s SHIELD supplement).
This level of disease control (no evidence of disease, regression, or stability) substantially exceeds typical clinical benefit and disease control rates reported with standard chemotherapy in advanced or pretreated solid tumors.
Important disclaimer note
This page summarizes an observational report based on self-reported patient outcomes. It is intended for educational purposes and should not be read as medical advice or a guarantee of results for any individual. The authors state that the findings are hypothesis-generating and that prospective, randomized, placebo-controlled trials are needed to better understand safety, effectiveness, and optimal dosing. Further studies are also warranted to confirm if ivermectin + mebendazole has prophylactic or preventative benefits for cancer.
- 84.4% reported a clinical benefit
- 32.8% reported No evidence of disease
- 15.6% reported tumor regression
Dr William Makis posted on X.com (April 2026):
 |
| Self-reported cancer outcomes at 6-month follow-up (N=122) |
Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort (2026)
Abstract
Background: Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies. Ivermectin and mebendazole have demonstrated multi-target anti-cancer activity in preclinical models, including the inhibition of cancer cell proliferation and the targeting of cancer stem cells. This paper evaluates real-world patient-reported outcomes, safety, and adherence in a cohort of cancer patients utilizing this combination protocol.Methods: We analyzed a prospective observational cohort of 197 cancer patients who were prescribed ivermectin and mebendazole off-label through a telemedicine platform by licensed U.S. healthcare providers. Participants received compounded oral capsules containing 25 mg ivermectin and 250 mg mebendazole. As part of a clinical program evaluation, data were collected via voluntary, standardized digital surveys at baseline and at approximately 6-month follow-up. Of the initial cohort (N = 197), baseline characteristics, including cancer type and disease status, were assessed. A total of 122 participants completed the follow-up survey (61.9% response rate) to evaluate self-reported cancer outcomes, medication adherence, and adverse events. 95% confidence intervals (CI) were calculated for primary outcome measures using the Wilson score method. Dose-stratified analyses for outcomes and safety were conducted using Chi-square statistics.
Results: The cohort represented a diverse clinical profile of cancer patients, with mean age of 67 years and nearly balanced sex distribution (52.3% male, 47.7% female). Cancer types included prostate (27.9%), breast (18.3%), lung (8.6%), colon (5.1%), urologic (4.6%), pancreatic (3.0%), liver (2.5%), gynecologic (2.5%), and hematologic (2.5%) malignancies. At enrollment, participants had a median duration since initial diagnosis of 1.2 years, with 37.1% experiencing active disease progression. At 6-month follow-up, medication adherence was high with 86.9% of participants completing the full initial 90-capsule ivermectin-mebendazole prescription and 66.4% remaining on the protocol at 6 months. The Clinical Benefit Ratio (CBR) was 84.4% (95% CI: 77.0–89.8%). Notably, 48.4% (95% CI: 39.7–57.1%) of the cohort reported the strongest positive outcomes, consisting of regression (15.6%; 95% CI: 10.2–23.0%) or no current evidence of disease (NED, 32.8%; 95% CI: 25.1–41.5%). Disease stability was reported to be maintained in 36.1% (95% CI: 28.1–44.9%) of participants, while 15.6% (95% CI: 10.2–23.0%) reported disease progression. While 25.4% reported mild side effects (primarily gastrointestinal), 93.6% of those affected continued treatment through minor dose adjustments. Some participants reported concurrent conventional therapies, including chemotherapy (27.9%), radiation therapy (21.3%), and surgery (19.7%), as well as adjunctive interventions such as supplement use (49.2%), dietary modification (37.7%), and other integrative approaches.
Conclusions: In this prospective real-world cohort, the combination of ivermectin and mebendazole was associated with high rates of self-reported clinical benefit, with nearly half of participants reporting tumor regression or no current evidence of disease across a heterogeneous population of cancer patients. These findings provide a compelling clinical signal that these well-tolerated, repurposed agents may offer therapeutic benefit. However, given the observational design, reliance on self-reported outcomes, and potential for selection bias and uncontrolled confounding, these findings should be interpreted as hypothesis-generating. Urgent prospective, randomized, placebo-controlled clinical trials are warranted to validate these observations and further define optimal dosing strategies.
Source and Reference: https://zenodo.org/records/19455636
Ivermectin + Mebendazole: An important tool in the battle against cancer
The exceptionally high self-reported Clinical Benefit Ratio (CBR) of 84.4% observed at the 6-month follow-up in this diverse real-world population is striking and underscores the potential clinical importance of the ivermectin and mebendazole combination. |
| Where to buy Ivermectin and Mebendazole Formula: Ivermectin and Mebendazole. |
This level of disease control (no evidence of disease, regression, or stability) substantially exceeds typical clinical benefit and disease control rates reported with standard chemotherapy in advanced or pretreated solid tumors.
Important disclaimer note
This page summarizes an observational report based on self-reported patient outcomes. It is intended for educational purposes and should not be read as medical advice or a guarantee of results for any individual. The authors state that the findings are hypothesis-generating and that prospective, randomized, placebo-controlled trials are needed to better understand safety, effectiveness, and optimal dosing. Further studies are also warranted to confirm if ivermectin + mebendazole has prophylactic or preventative benefits for cancer.
.png)
.png)
Comments
Post a Comment